Victory Capital Management’s Janux Therapeutics JANX Stock Holding History

Victory Capital Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.4K	Hold	5,953	–	–	﹤0.01%	2335
2026 Q1	$82.7K	Hold	5,953	–	–	﹤0.01%	2281
2025 Q4	$82.2K	Buy	5,953 +1,090	+22%	+$25.6K	﹤0.01%	2288
2025 Q3	$119K	Sell	4,863 -177,203	-97%	-$4.32M	﹤0.01%	2279
2025 Q2	$4.21M	Sell	182,066 -83,585	-31%	-$2.2M	﹤0.01%	1367
2025 Q1	$7.17M	Buy	265,651 +23,242	+10%	+$876K	0.01%	1171
2024 Q4	$13M	Buy	242,409 +212,664	+715%	+$11.2M	0.01%	992
2024 Q3	$1.35M	Buy	29,745 +17,525	+143%	+$762K	﹤0.01%	1646
2024 Q2	$512K	Buy	+12,220	New	+$574K	﹤0.01%	1971

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Victory Capital Management's JANX Position: Q2 2026 in Review

Victory Capital Management held its Janux Therapeutics (JANX) position steady in Q2 2026 at 5,953 shares worth $91.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2335.

Victory Capital Management first reported a position in JANX in Q2 2024 and has held it in 9 quarters since. The position peaked at $13M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Victory Capital Management held 5,953 shares of Janux Therapeutics worth $91.4K as of Q2 2026.
Victory Capital Management left its Janux Therapeutics share count unchanged in Q2 2026.
Janux Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2335 holding.
Victory Capital Management first reported a position in Janux Therapeutics in Q2 2024 and has held it in 9 quarters since.
Victory Capital Management's Janux Therapeutics position peaked at $13M in Q4 2024.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.